Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Commentary|Podcasts|November 30, 2023
Managed Care Cast Presents: Insights Into Precision Medicine in NSCLC
In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.
Advertisement
Today we are bringing you a conversation between 3 experts on precision medicine in non–small cell lung cancer (NSCLC).
Martin Socinski, MD, executive director of the AdventHealth Cancer Institute, spoke with Martin Dietrich, MD, PhD, medical oncologist of Florida Cancer Specialists and Research Institute, and Joshua Sabari, MD, medical oncologist with NYU Langone Health Perlmutter Cancer Center and assistant progessor in the Department of Medicine at NYU Grossman School of Medicine.
Advertisement
Related to this article
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
2
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
5